
Nova Biomedical: Innovating immune balance restoration for solid organ transplant patients.
Founded with a mission to restore immune balance in patients receiving solid organ transplants, TRACT Therapeutics is pioneering personalized medical solutions. The company’s core product, TregCel™, utilizes a patient's own regulatory T cells, expanded in a lab and re-infused to establish immune tolerance. This innovative approach aims to improve outcomes for transplant patients and those suffering from autoimmune disorders, focusing on personalized and effective treatments.
TRACT Therapeutics has attracted attention from notable investors and experts in the biotech industry. The company’s advancements have been recognized for their potential to significantly impact transplant medicine and autoimmune disease management. By leveraging cutting-edge science and technology, TRACT Therapeutics is poised to make substantial contributions to patient care and the broader medical community.

Tr1x
tr1x.bio

Sonoma Biotherapeutics

Tactiva Therapeutics

TregTherapeutics

Abata Therapeutics
abatatx.com

TRex Bio
trex.bio

GentiBio
gentibio.com

Tmunity Therapeutics

Janux Therapeutics
januxrx.com

Medeor Therapeutics
medeortx.com

Trefoil Therapeutics

Endogena Therapeutics

Celularity
celularity.com

Akttyva Therapeutics
akttyva.com

Modulus Therapeutics
Companies similar to Tract Therapeutics include Tr1x, Sonoma Biotherapeutics, Tactiva Therapeutics and TregTherapeutics.
Tract Therapeutics was founded in 2013.
Tract Therapeutics' headquarters is located in Chicago, IL, US.
Tract Therapeutics' most recent funding round was for $15M (USD) in March 2019.
As of Mar 18, 2019, Tract Therapeutics has raised a total of $15M (USD).
Tract Therapeutics has 5 employees as of Feb 5, 2024.